Objective To compare the treatment of childhood immune thrombocytopenia (ITP) with historical practice in the UK.
Design Data collection through a national UK Childhood ITP registry (http://www.uk-itp.org) started in January 2007.
Settings UK hospitals.
Participants Children admitted with a new diagnosis of acute ITP and their treating physicians.
Main outcome measures Bleeding severity, platelet count, disease management and outcome from the time of presentation to 6 months.
Results Data from 225 children were analysed. 54% of children had clinically mild, 42% had moderate and 4% had severe disease as defined previously.1 The mean platelet counts at diagnosis for these groups were 14, 8 and 6×109/l respectively. Children with mild disease had fewer bleeding sites (1.9), compared with moderate (2.5) or severe disease (3.6). There was one intracranial haemorrhage reported. At 6 months' follow-up, 32% had a persistent platelet count <150×109/l, but only 4.8% had a count <20. The proportion of UK children receiving platelet-raising treatment was noted to decrease from 61% in 1995 to 38% in 2000. The current UK 2009 registry data show a continued decrease in treatment to 16% of all the children. In contrast, historical international data report 69% of children receiving interventional therapy.
Conclusion The current UK practice has shown a continued reduction in the number of children receiving treatment in comparison with historical data and international practice.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Funding The childhood ITP registry is supported by charitable donation for the ITP Support Association.
Competing interests JDG: honoraria for participation on advisory boards for GSK, Amgen and Baxter; research support from Baxter. PHB-M: participation in advisory board meetings for Amgen and GSK; chair of a satellite meeting for Baxter at BSH 2009; support for travel to international meetings by Baxter.
Patient consent Obtained.
Ethics approval Ethics approval was provided by the Northern NRES.
Provenance and peer review Not commissioned; externally peer reviewed.